source
- Biogen’s ALS drug shows symptom improvement in some patients three years after approvalBiogen’s antisense therapy tofersen, marketed as Qalsody, received FDA approval three years ago as the first treatment to target a genetic form of ALS linked to the SOD1 gene. Since then, a number…
- BMS commits $2.3 billion to build modular manufacturing campus in Houston, creating 2,500 jobsBristol Myers Squibb announced a $2.3 billion investment to construct a new manufacturing campus in Houston, Texas. The site will cover about 600,000 square feet and is designed to be modular, allo…